Venture Life Group Plc · LSE:VLG
Venture Life — FY2025/26 Earnings Presentation
23 slides from Venture Life's earnings presentation, 2026
Slide 1: 2025/26 Results Presentation
2025/26 Results Presentation Proactive Healthy Longevity 1
Slide 2: Agenda & Presenters
Agenda & Presenters Overview – A Transformational Period Jerry Randall, Chief Executive Officer Financial Performance Danny Wells, Chief Financial Officer Commercial, Marketing and Innovation Progress Kate Bache, Chief Innovation & Marketing Officer and Gervase Fernandes, Strategic Growth Director S
Slide 3: Venture Life At a Glance
Venture Life At a Glance Growing Categories Strong Brand Portfolio Innovation Engine 4 Key Categories 8 Brands 19 Product Launches Targeting categories with strong structural In the areas of Women’s Intimate Health, During FY2025/26 tailwinds and headroom for growth Hormonal Health, Diabetes Managem
Slide 4: A Transformational Reporting Period
A Transformational Reporting Period Simplified our portfolio, strengthened our balance sheet and repositioned the Group as a pure-play consumer healthcare business. Financial & Operational Successful Pivot to Growth Drivers Highlights Pureplay Strategy 17.0% revenue growth delivered by our Simplifie
Slide 5: Financial Performance
Financial Performance 5
Slide 6: FY2025/26 Financial Performance
FY2025/26 Financial Performance £50.0m £22.3m £7.9m Revenue Gross Profit Adjusted1 EBITDA +16.0% LFL (2024: £12.2m) +19% on LTM2 basis 5.8 pence £3.5m £11.5m Adjusted3 Diluted EPS Free Cash Flow Cash (2024: 3.1 pence) (2024: £3.7m) (2024: Net debt £18.8m) 1 Adjusted EBITDA and EPS is EBITDA before d
Slide 7: Strong Revenue Performance Across Our Power Brands
F pe inan rfo cia rm an l ce Strong Revenue Performance Across Our Power Brands 12 Month Rolling Revenue Performance Revenue By Therapy Area 17 Month Revenue Performance 12Emths 12Emths 17mths 31-May-26 9.1 11.4 6.6 8.5 2.9 31-May-26 £35.6 £3.0 £3.3 £46.7 31-May-26 12mths 31-Dec-25 8.8 10 5.8 8.5 2
Slide 8: Gross Margin Improvement Through Transformation Activities
F pe inan rfo cia rm an l ce Gross Margin Improvement Through Transformation Activities 60.0% FY25/26 Gross Margin reduced slightly versus FY24 but has improved materially compared 50.0% to pre-divestment levels, reflecting Power Brand focus 40.0% FY25/26 product mix adversely impacted by ordering p
Slide 9: LTM Adjusted EBITDA gaining momentum ahead of FemiClear and CUROXEN acquisition
F pe inan rfo cia LTM1 Adjusted EBITDA gaining momentum ahead of FemiClear and rm an l ce CUROXEN acquisition post period-end 14,000 Operating cost base temporarily lost leverage 12,000 following divestments 10,000 Operating costs increased reflecting full year impact of 8,000 acquisition, increased
Slide 10: Cash Flow and Net Cash Movement
F pe inan rfo cia rm an l Cash Flow and Net Cash Movement ce Cash balance remains strong after investment in FemiClear c.£56m cash proceeds from Operating cash conversion divestments, used to repay Cash transferred at period- of 56.2% and Free Cash Flow £56.1 end for acquisition of ↑ borrowings, inv
Slide 11: Commercial, Marketing and Innovation Progress
Commercial, Marketing and Innovation Progress 11
Slide 12: Hormonal Health
Hormonal Health +28% 61k (+6%) Revenue Dist. Points Long-Term Growth Proven Momentum Near-Term Growth Drivers UK’s No.1 Menopause Brand (Circana Distribution increases (+6%) across key Increased focus on US retail growth over Value Sales Data) strategic customers in UK, USA, and EU the next 12 month
Slide 13: Women's Health
Women's Health +15% 17k (+5%) Revenue Dist. Points Long-Term Growth Proven Momentum Near-Term Growth Drivers UK’s No.1 Bacterial Vaginosis Brand Retail distribution increases across UK High Two new UK retailers launching the (Circana Value Sales Data) Street chains (+5%) Balance Activ range in 2026/
Slide 14: Energy Management
Energy Management +16% 8k Revenue Dist. Points Long-Term Growth Proven Momentum Near-Term Growth Drivers NICE recommended for T1D hypo Excellent growth in online sales (+27.1%) and USA expansion into retail presenting a large management and NHS first line treatment pharmacy channel (+10.9%) opportun
Slide 15: Ear Care
Ear Care +7.9% 7.4k (+40%) Revenue Dist. Points Long-Term Growth Proven Momentum Near-Term Growth Drivers No.1 recommended by audiologists (93% of Retail Distribution increases across UK New packaging look and feel will improve ear care specialists*) High Street in 2k+ additional stores standout and
Slide 16: Vaginal Health
Vaginal Health +30% 74k (+69%) Revenue Dist. Points Long-Term Growth Proven Momentum Near-Term Growth Drivers Proprietary, patented, clinically proven Step-changing distribution increases driven Expanding successful optimisation of retail formulas protected by 4 patents by increased distribution in
Slide 17: Innovation
Innovation VLG’s unique combination of deep and varied insight with an entrepreneurial approach drives our cutting-edge innovation engine Hormonal Health Intimate Health Energy Management Extensions of core Stretching / Breakthrough Pharmaceuticals + Symptom-led self- Chronic, recurrent Trends Longe
Slide 18: Strategic Update & Outlook
Strategic Update & Outlook 18
Slide 19: Our transformation to a growing pure-play consumer healthcare business
Our transformation to a growing pure-play consumer healthcare business Building a portfolio of trusted, science-backed brands that support proactive healthy longevity, underpinned by our five strategic pillars THEN ACQUISITONS TODAY Vertically integrated Focused, asset-light and ready to execute v C
Slide 20: Significant market powered by long-term structural tailwinds
Significant market powered by long-term structural tailwinds Structural shifts are driving sustainable demand for proactive, preventative healthcare Microbiome & holistic health awareness Distrust of reactive “sick-care” Significant and growing opportunity for Destigmatisation of taboo health topics
Slide 21: Unlocking new markets through considered, strategic M&A
Unlocking new markets through considered, strategic M&A £500m US retail FemCare market entry The FemiClear acquisition opens two complementary growth platforms Shared consumer needs across the UK and US create a repeatable opportunity to enter new geographies and expand into adjacent Women’s Intimat
Slide 22: Our evolution and growth ambition
Ou ro utl oo k Our evolution and growth ambition Four growth levers translate our ambition into delivery, targeting white space in existing and adjacent categories FY25/26 (Actuals) FY26/27 (Guidance) 2030+ (Ambition) £50.0m Revenue £54.7m Revenue £300m+ Revenue £7.9m Adjusted EBITDA £11.6m EBITDA 2
Slide 23: Disclaimer
Disclaimer The information contained in this presentation (the “Presentation”) has been prepared by Venture Life Group plc (the “Company”) for information purposes only. It has not been independently verified and does not purport to be comprehensive. No representation or warranty, express or implied